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http://dx.doi.org/10.1016/j.stemcr.2016.10.006SUMMARYWe studied the function of the G-protein-coupled receptor PAR1 inmediating the differentiation ofmouse embryonic stem cells (mESCs)
to endothelial cells (ECs) that are capable of inducing neovascularization. We observed that either deletion or activation of PAR1 sup-
pressed mouse embryonic stem cell (mESC) differentiation to ECs and neovascularization in mice. This was mediated by induction of
TGFbRII/TGFbRI interaction, forming an active complex, which in turn induced SMAD2 phosphorylation. Inhibition of TGF-b signaling
in PAR1-deficient mESCs restored the EC differentiation potential of mESCs. Thus, PAR1 in its inactive unligated state functions as a scaf-
fold for TGFbRII to downregulate TGF-b signaling, and thereby promote ESC transition to functional ECs. The PAR1 scaffold function
in ESCs is an essential mechanism for dampening TGF-b signaling and regulating ESC differentiation.INTRODUCTION
G-protein-coupled receptors (GPCRs), such as PAR1 (Prote-
ase Activated Receptor 1, also referred to as CF2R, F2R,
TR, and HTR), are transmembrane receptors that transmit
extracellular signals into cells by coupling to specific heter-
otrimeric guanine nucleotide binding proteins (G proteins)
and thus mediate an array of responses (Rosenbaum et al.,
2009; Vassart and Costagliola, 2011). G-protein-activated
pathways constitute the largest class of therapeutic targets
(Ding et al., 2015; Thompson et al., 2005). The function
ascribed to GPCRs is the result of agonist binding to the re-
ceptor, resulting in activation of specific G proteins such as
stimulatory Gas and inhibitory Gai subunits, which selec-
tively activate or inactivate effector pathways to mediate
the desired responses (Kobilka, 2007; Wess, 1997). How-
ever, little is known about the role of GPCRs in mediating
the differentiation of stem cells to terminally differentiated
cells (Callihan et al., 2011; Kobayashi et al., 2010). To date,
work has centered on pathways in adult stem cells such
as signals emanating from specialized GPCRs (Frizzled pro-
teins) of the WNT pathway and chemokine receptors such
as CXCR4 expressed in stem cells (Holland et al., 2013; Van
Camp et al., 2014). The role of GPCR signaling in medi-
ating the differentiation of pluripotent embryonic stem
cells (ESCs) into differentiated cells has not been widely
explored.
ESCs are critical for regenerative therapies because unlike
adult stem cells they expand indefinitely and are ideal for
generating mature cells to replace injured tissue. Studies
showed that the transcriptional programs underlying ESC1050 Stem Cell Reports j Vol. 7 j 1050–1058 j December 13, 2016 j ª 2016
This is an open access article under the CC BY license (http://creativecommodifferentiation mirror those during embryonic develop-
ment (James et al., 2005; Shiraki et al., 2014). One example
is the differentiation of ESCs into regenerative vascular
endothelial cells (ECs), which requires upregulation of
the developmental transcription factors such as ER71
(Kohler et al., 2013) and which serves as a window for
investigation of signaling pathways mediating vascular
regeneration in ischemic tissue. Here we used a GPCR
gene expression screen to identify GPCRs expressed in
mouse ESCs (mESCs) undergoing differentiation to ECs.
We observed that PAR1was highly upregulated, and further
that it was required for EC differentiation. PAR1 functions
as a scaffold for the transforming growth factor b (TGF-b)
receptor TGFbRII, which thereby dampens SMAD signaling
and activates the transition of ESCs to ECs capable of
forming new blood vessels.RESULTS
PAR1 Expression in mESCs Differentiating into ECs
To identify the GPCRs regulating mESC differentiation to
ECs, we first performed a GPCR screen made up of 534
GPCRs and related G proteins in mESCs andmESC-derived
ECs (mESC-ECs). Three groups of GPCR genes were iden-
tified: (1) low expression in undifferentiated mESCs and
high expression in mESC-derived ECs; (2) high expression
in undifferentiated mESCs and low expression in mESC-
ECs; and (3) high expression in both undifferentiated
mESCs andmESC-ECs.We focused on the third group con-
sisting of 74 genes having greater than four mRNA copiesThe Author(s).
ns.org/licenses/by/4.0/).
Figure 1. Expression of PAR1 in mESCs
and ECs
(A) Gene expression profile of 534 GPCRs
and other G proteins showed that 74 and
160 genes in mESCs and mESC-ECs, respec-
tively, expressed greater than four copies of
mRNA, within which expression of a subset
of 11 listed genes was elevated greater than
20-fold. Results are from two independent
experiments.
(B) Comparison of mRNA expression of the
four protease-activated receptors (PARs) in
mESCs and mESC-ECs.
(C) PAR1 mRNA expression in mESCs
and mESC-ECs measured by real-time qPCR
shown as mean ± SD (n = 3 independent
experiments, *p < 0.05).
(D) PAR1 and VE-cadherin protein expres-
sion in mESCs and mESC-ECs shown in
duplicate samples. VE-cadherin is expressed
only in ECs derived from ESCs.in the undifferentiated mESC state and 160 genes
having greater than four copies in mESC-ECs (Figures 1A
and S1). Among the highly expressed genes, 11 were upre-
gulated greater than 20-fold in mESC-ECs; specifically the
orphan receptor GPR56 (Huang et al., 2008; Jin et al.,
2009) was the highest in this category (Figure 1A). PAR1
was the second highest, increasing 48-fold from mESCs
to ECs (Figures 1A and 1B). Expression of other PAR genes
in ESCs was either unchanged (PAR2) or not evident
(both PAR3 and PAR4) (Figure 1B). Furthermore, marked
PAR1 upregulation was confirmed by real-time qPCR (Fig-
ure 1C) and western blotting (Figure 1D), validating the
screen results. VE-cadherin expression was increased in
mESC-ECs (Figure 1D), showing the successful transition
of ESCs to ECs.
Suppression of PAR1 Expression in mESCs Prevents
Differentiation to ECs
To address the role of PAR1 in regulating mESC differen-
tiation to ECs, we knocked down PAR1 using lentivirus-
mediated small hairpin RNA (shRNA) inserted into a
pLKO1-Puro lentivirus vector (Figure 2A) or deleted PAR1
using CRISPR/Cas9 (Figures 2D and S2). These cells were
then differentiated to ECs (Kohler et al., 2013). We
observed by fluorescence-activated cell sorting (FACS) anal-
ysis that suppression of PAR1 expression markedly reducedthe generation of FLK1+VE-cadherin+ ECs compared with
control ESCs (Figures 2B, 2C, and 2E).
To address whether suppression of PAR1 expression per
se prevented the generation of ECs, we carried out a rescue
experiment in which PAR1 was re-expressed in PAR1-
knockdown (PAR1 KD) mESCs by adenovirus transduction
using FLAG-tagged human PAR1 (hPAR1). In the rescue
experiments, we observed restoration of VE-cadherin and
FLK1 expression (Figures 2F–2H), indicating the requisite
role for PAR1 in signaling ESC differentiation to ECs. Inter-
estingly, in PAR1 KD studies, we observed that although
PAR1 expression was initially suppressed by shRNA it
recovered within 4 days (Figure 2F) due to endogenous
PAR1 upregulation during EC differentiation (Figure 1C);
however, in knockdown cells the initial period of PAR1
KDwas in fact sufficient to suppress and delay VE-cadherin
and FLK1 expression (Figure 2F).
We also observed that GFP-labeled control ESC-ECs
formed functional blood vessels in implanted Matrigel
plugs as evident by staining for intraluminal erythro-
cytes, whereas PAR1-deficient ESC-ECs failed to form
any functional vessels (Figure 2I). Importantly, the
expression of hPAR1 in mPAR1-deficient ESC-ECs
rescued the ability to form vessels (Figure 2I). Quantifica-
tion of vessels in explanted Matrigel plugs confirmed
decreased blood vessel formation in the PAR1-deficientStem Cell Reports j Vol. 7 j 1050–1058 j December 13, 2016 1051
Figure 2. PAR1 Regulates Differentia-
tion of mESCs to ECs
(A) Representative western blots showing
expression of PAR1 in scrambled (Ctrl) and
PAR1 shRNA lentivirus-treated (KD) mESCs.
Results are representative of three inde-
pendent experiments.
(B) FACS analysis of FLK1 and VE-cadherin
(VE-cad) expression in control (Ctrl) or
PAR1 KD mESCs at 7 days after applying
EC differentiation condition. PAR1 KD
suppressed the generation of VE-cadherin+
FLK1+ cells. Mouse IgG1 kappa and rat
IgG2a kappa were used as negative controls
for VE-cadherin and FLK1 in FACS gating.
The outlined cell population indicates
double-positive endothelial cells.
(C) Data in (B) presented as percentage of
FLK1+VE-cadherin+ ECs (mean ± SD; n = 3
independent experiments).
(D) Representative western blots showing
expression of PAR1 in wild-type (Wt) and
PAR1-deleted (Par1/) mESCs as induced
by CRISPR/Cas9 from three independent
experiments.
(E) Quantification of FLK1+VE-cadherin+
ECs by flow cytometry at 7 days after
inducing differentiation of Wt and
Par1/ mESCs (n = 3 independent ex-
periments).
(F) Transduction of mESCs with control
or PAR1 shRNA lentivirus or co-trans-
duction of adenovirus encoding FLAG-
hPAR1 followed by differentiation of
mESCs into ECs. Cells were harvested
at the indicated times and used for
western blot analysis. Expression of
VE-cadherin, FLK1, and FLAG-PAR1 was
determined.
(G and H) Quantification of changes in expression of FLK1 (G) and VE-cadherin (H) proteins (mean ± SD, n = 3 independent experiments).
(I) Representative confocal microscopic images of the erythrocyte marker TER-119 (used to identify functional blood vessels) and EGFP in
Matrigel plugs retrieved 7 days after transplantation of purified CD31+ ECs derived from control, PAR1 KD, and hPAR1+PAR1 KD mESCs.
Control but not PAR1 KD mESC-ECs formed functional vessels in vivo as indicated by erythrocyte staining, whereas hPAR1 overexpression in
PAR1 KD mESCs rescued functional blood vessel formation. Green (EGFP) indicates microvessels generated from transplanted mESC-ECs.
Scale bar, 20 mm.
(J) Quantification of vessels seen per field (103) in H&E staining (n = 3–4 mice per group). The number of vessels decreased in Matrigels
from PAR1 KD mESC-ECs and restored in cells re-expressing hPAR1. Data are expressed as mean ± SD of vessels seen (number of vessels was
calculated from six fields per Matrigel sample from each mouse; the mean for a group represents the average vessel number from n = 3–4
mice per group).ESC-ECs and their restoration by re-expression of hPAR1
(Figure 2J).
Inhibition of TGF-b Signaling Overcomes EC
Differentiation Block Induced by Deletion of PAR1
Wenext addressed whether PAR1 enhanced the generation
of ECs through inhibition of TGF-b signaling based on the1052 Stem Cell Reports j Vol. 7 j 1050–1058 j December 13, 2016postulated inhibitory role of TGF-b signaling in EC differ-
entiation (Ginsberg et al., 2012; Guo and Chen, 2012;
James et al., 2010). We observed that PAR1 KD by shRNA
or PAR1 knockout by CRISPR/Cas9 in each case upregu-
lated the expression of TGFbRII (Figures 3A–3C). We also
observed that SMAD2 phosphorylation was significantly
increased in PAR1 KD ESCs (Figures 3D and 3E), indicating
Figure 3. Inhibition of TGF-b Signaling Mediates Transition of mESCs to ECs
(A) Immunoblots of TGFbRI and TGFbRII proteins in mESCs transduced with scrambled control or PAR1 shRNA lentiviruses.
(B) Quantification of TGFbRII expression in (A) showing increased expression in response to PAR1 knockdown (KD) (mean ± SD, n = 3
independent experiments).
(C) Expression of TGFbRII protein in wild-type (Wt) or Par1/mESCs showing increased TGFbRII expression in PAR1-null cells. Results are
representative of two independent experiments.
(D) mESCs transduced with control or PAR1 shRNA lentivirus or co-transduced with adenovirus encoding FLAG-hPAR1, then differentiated
into ECs. Expression of NANOG, PAR1, and phospho-SMAD2 as well as total SMAD2 was determined. Upon knockdown of PAR1, expression of
NANOG temporally decreased, paralleling the increased phosphorylation of SMAD2.
(E) Quantification of phospho-SMAD2 expression in response to depletion of PAR1 or overexpression of hPAR1 in (D) (mean ± SD, n = 3
independent experiments).
(F) Quantification of NANOG expression in response to depletion of PAR1 or expression of hPAR1 in (D) (mean ± SD, n = 3 independent
experiments). NS, not significant.
(G) Augmented phospho-SMAD2 expression as determined by western blot in Par1/ mESCs, which was prevented by treatment with
TGFbRI inhibitor SB-431542. Results are representative of two independent experiments.
(H) Representative FACS data showing FLK1+VE-cadherin+ ECs derived from Wt and Par1/ mESCs at 7 days after applying EC differen-
tiation conditions in the presence or absence of SB-431542. Mouse IgG1 kappa and rat IgG2a kappa were used as negative controls for FACS
gating. The outlined cell population indicates double-positive endothelial cells.
(I) Percentage of FLK1+VE-cadherin+ cells derived from FACS experiments in (H) (mean ± SD, n = 3 independent experiments).the downstream activation of TGF-b signaling. Deletion
of PAR1 by CRISPR/Cas9 similarly enhanced SMAD2
phosphorylation (Figure 3G). However, re-expression of
hPAR1 reduced SMAD2 phosphorylation to basal levels
(Figures 3D and 3E). Importantly, the TGF-b inhibitor
SB431542 restored mESC transition to ECs (Figures 3Hand 3I), indicating that the effect of PAR1 depletion was
secondary to enhanced TGF-b signaling.
As phospho-SMAD2 binds the NANOG promoter and
upregulates its expression (Sun et al., 2014), we also deter-
minedNANOG expression in PAR1 KD cells.We found that
NANOG expression decreased progressively over the 6-dayStem Cell Reports j Vol. 7 j 1050–1058 j December 13, 2016 1053
period in control ESCs undergoing differentiation into
ECs (Figure 3F), consistent with the loss of pluripo-
tency. In contrast, NANOG expression remained elevated
throughout the differentiation period in PAR1 KD ESCs
(Figure 3F), whereas expression of hPAR1 in PAR1 KD
ESCs restored the downregulation of NANOG (Figure 3F).
PAR1 Induces EC Generation through Binding of
TGFbRII
We next addressed mechanisms of PAR1 regulation of ESC
transition to ECs via modulation of TGF-b signaling. Here
we first examined the specific effects of PAR1 activation
on SMAD2 phosphorylation and the subsequent EC gener-
ation. SMAD2 phosphorylation was increased in ESCs
following PAR1 activation induced by the PAR1-activating
peptide (PAR1-AP) (Figure 4A). Furthermore, this response
was prevented by inhibiting TGF-b signaling using
SB431542 (Figure 4A). Since PAR1 knockdown or deletion
activated TGF-b (SMAD-2 phosphorylation) signaling (Fig-
ures 3D, 3E, and 3G) and thereby reduced the generation of
ECs (Figures 3H and 3I), we next addressed the effects of
PAR1 activation. Here, surprisingly, we observed that
PAR1 activation also reduced the generation of VE-cadher-
in+FLK1+ ECs from ESCs (Figures 4B and 4C).
To address mechanisms by which PAR1 activation down-
regulated the differentiation of ECs, we examined the inter-
action of TGFbRII with TGFbRI, a requirement for activa-
tion of downstream TGF-b signaling (Huang and Chen,
2012; Zuniga et al., 2005).We observed that the association
of TGF-b receptors and subsequent activation of TGF-b
signalingwas increased in PAR1-deletedmESCs (Figure 4D).
In addition, we stimulated mESCs with a specific PAR1-AP
(Citron et al., 2016; Gutierrez-Rodriguez and Herranz,
2015) to determine whether activation of PAR1 promoted
the binding of TGF-b receptors and thereby activated
TGF-b signaling (described in Figure 4A). Here we found
that PAR1 activation with PAR1-AP indeed induced
TGFbRII/TGFbRI interaction (Figure 4E), an effect also
seen in the control experiment following TGF-b1 stimula-
tion (Figure 4E). However, this interaction of TGFbRII
with PAR1 was only evident when PAR1 was in the unli-
gated state (Figure 4E). Thus, PAR1 in the inactive state
bound TGFbRII and prevented TGFbRII interaction with
TGFbRI to inhibit TGF-b signaling.
To validate this model, we studied the effects of overex-
pressing FLAG-tagged PAR1, and observed that it induced
TGFbRII/FLAG-PAR1 association as well as the uncoupling
of TGFbRII and TGFbRI (Figure 4F). To identify whether
PAR1 can also bind TGFbRI, we expressed FLAG-PAR1 and
His-tagged TGFbRI in 293T cells and carried out co-immu-
noprecipitation experiments using either anti-FLAG-tag
or anti-His-tag antibody. However, we failed to detect an
interaction between PAR1 and TGFbRI (Figure 4G). Thus,1054 Stem Cell Reports j Vol. 7 j 1050–1058 j December 13, 2016it appears that TGFbRII binds either inactive PAR1 or
TGFbRI, but not both simultaneously, and that TGFbRI
does not bind PAR1.
Our results support amodel in which PAR1 functions as a
scaffold for TGFbRII to inhibit downstreamTGF-b signaling
that is activated by TGFbRII binding to TGFbRI (Figure 4H).
The inhibition of TGF-b signaling in turn activates ESC
differentiation to ECs and induces neovascularization.
Conversely, either depletion of PAR1 or activation of
PAR1 results in default dimerization of TGFbRII and
TGFbRI to activate TGF-b signaling and hence suppress
mESC differentiation to ECs and neovascularization.DISCUSSION
Studies in Par1/ mouse embryos showed that PAR1 is a
key regulator of vascular development; that is, 50% of
Par1/mice died in utero because of defective vasculogen-
esis (Griffin et al., 2001). PAR1 utilizes multiple heterotri-
meric G proteins, Gai, Gaq, and Ga12/13, to transmit
intracellular signals (Coughlin, 2000; Soh et al., 2010).
Only EC-specific Ga13/ embryos died at embryonic
days 9.5–11.5 with a phenotype resembling the Par1/
mice (Ruppel et al., 2005). Furthermore, embryos re-ex-
pressing Ga13 in ECs did not differ from their Ga13/ lit-
termates and also showed intracranial bleeding (Ruppel
et al., 2005), pointing to a key function of PAR1 indepen-
dent of its associated canonical heterotrimeric G-protein
signaling.
In the present study, we carried out an expression
profile analysis of GPCRs in mESCs and mESC-derived
ECs, and observed inordinately high expression of
the orphan receptor GPR56 (Huang et al., 2008) and,
importantly, of PAR1 in the ECs generated from ESCs.
We focused on PAR1 not only as it is highly expressed
in ESCs but also because of its presumptive role in
vascular development shown in Par1/ embryos (Griffin
et al., 2001). Our results demonstrate that PAR1 expres-
sion mediates the differentiation of mESCs to ECs, which
were functional as evident by their ability to form vessels
in Matrigel plugs in vivo. Intriguingly, downregulation
of PAR1 expression as well as direct agonist activation
of PAR1 suppressed neovascularization through forcing
the association of TGFbRII to TGFbRI, and thereby acti-
vating TGF-b signaling (Figure 4H). PAR1 in its inactive
state prevented TGF-b signaling by binding TGFbRII,
and thus blocked the TGFbRII interaction with TGFbRI
required for activation of the TGF-b pathway (Vargel
et al., 2016). However, in the absence of PAR1, TGFbRII
was free to bind TGFbRI resulting in unfettered TGF-b
signaling, which also blocked mESC differentiation
to ECs.
Figure 4. PAR1 Scaffolds TGFbRII to Sup-
press TGF-b Signaling and Generate VE-
Cadherin+FLK1+ Cells
(A) Expression of phospho-SMAD2 and total
SMAD2 determined by western blot in
mESCs challenged with PAR1-AP (15 mM)
in the presence or absence of SB-431542
(10 mM). Results are from two independent
experiments.
(B) PAR1-induced activation of SMAD2
phosphorylation reduces generation of FLK1+
VE-cadherin+ cells. FACS analysis of FLK1 and
VE-cadherin expression in PBS or PAR1-AP-
treated (15 mM) mESCs at 7 days after initi-
ation of EC differentiation protocol. Mouse
IgG1 kappa and rat IgG2a kappa were used
as negative controls for FACS gating.
(C) Reduced generation of FLK1+VE-cad-
herin+ ECs assessed from data in (B) (mean ±
SD, n = 4 independent experiments).
(D) Deletion of PAR1 promotes TGFbRII
interaction with TGFbRI. Wild-type (Wt) or
Par1/ mESCs were harvested in modified
RIPA buffer and cell lysates were immuno-
precipitated (IP) with mouse anti-TGFbRII
antibody. Immunoprecipitates were blotted
with rabbit anti-TGFbRI or anti-TGFbRII
antibody. Results are representative of two
independent experiments.
(E) Activation of PAR1 with PAR1-AP pro-
motes TGFbRII interaction with TGFbRI.
mESCs were stimulated with PBS, PAR1-AP
(15 mM), or TGF-b (10 ng/mL), which served
as a positive control. Cell lysates were
then immunoprecipitated with mouse anti-
TGFbRII antibody, and immunoprecipitates
were blotted with rabbit anti-PAR1, anti-
TGFbRI, or anti-TGFbRII antibody. Results are representative of two independent experiments.
(F) TGFbRII fails to bind TGFbRI in the presence of unligated PAR1. mESCs were transduced with adenovirus encoding empty vector
or FLAG-PAR1, and harvested in modified RIPA buffer. Cell lysates were immunoprecipitated with rabbit anti-TGFbRII antibody and
immunoprecipitates were blotted with mouse anti-FLAG, anti-TGFbRII antibody, or goat anti-TGFbRI antibody. Results are representative
of two independent experiments.
(G) PAR1 in unligated state fails to bind TGFbRI. 293T cells were transfected with plasmids encoding empty vector, FLAG-PAR1, or 63His-
TGFbRI and harvested in modified RIPA buffer. Cell lysates were immunoprecipitated with mouse anti-FLAG or anti 63His antibody and
immunoprecipitates were blotted with rabbit anti-PAR1 or anti-63His antibody. Results are representative of two independent
experiments.
(H) Model describing PAR1 regulation of EC differentiation from ESCs. PAR1 functions as a scaffold, which suppresses TGFbRII activity by
competing with TGFbRI for TGFbRII binding. This in turn decreases expression of NANOG and facilitates differentiation toward the EC fate.
During PAR1 activation, TGFbRII disassociates from PAR1 and associates with TGFbRI, resulting in TGF-b pathway activation and SMAD2
phosphorylation. In the absence of PAR1, TGFbRII is able to freely associate with TGFbRI to activate TGF-b signaling, and thereby inhibit
ESC differentiation to ECs.In contrast to PAR1, expression of PAR2 (another PAR
family member) was not increased in ECs derived from
ESCs. PAR3 and PAR4 are also like PAR1 in that they are
ligated by thrombin or specific PAR3 and PAR4 agonists
(Dery et al., 1998), but they were not significantly ex-pressed in ESCs at baseline. Thus, we focused on the role
of PAR1 in regulating mESC differentiation to ECs.
Although we cannot rule out the contribution of these
PAR family members, they would appear to be less impor-
tant in regulating the transition of ESCs to ECs basedStem Cell Reports j Vol. 7 j 1050–1058 j December 13, 2016 1055
on the 48-fold increase in PAR1 expression compared with
the other PARs.
We observed that although PAR1 expression was initially
suppressed by shRNA, it recovered within 4–5 days
of initiating differentiation due to marked endogenous
PAR1 upregulation occurring during this period. The in-
crease in endogenous PAR1 expression was associated
with reduced SMAD2 phosphorylation as evident at
6 days. Importantly, however, knockdown of PAR1 during
this initial period of differentiation was in fact sufficient
to suppress and delay VE-cadherin and FLK1 expression,
suggesting that TGF-b signaling is a critical determinant
of EC lineage commitment in this phase.
We determined NANOG expression in PAR1 KD ECSs
undergoing differentiation to ECs to assess changes in their
pluripotency state. NANOG expression decreased in a
time-dependentmanner in control ESCs undergoing differ-
entiation, indicating loss of pluripotency. In contrast,
expression of NANOG was elevated throughout the differ-
entiation period in PAR1 KD ESCs. This finding is consis-
tent with the evidence that phospho-SMAD2 binding
to the NANOG promoter upregulates its expression (Sun
et al., 2014).
The finding that inhibition of TGF-b signaling overcame
the block in EC differentiation induced by upregulated
TGF-b signaling is consistent with the role of suppressed
TGF-b signaling as a central mechanism facilitating the
generation of ECs from ESCs (James et al., 2010). We
showed that the inactive PAR1 functioned as a scaffold
for TGFbRII, and restrained the dimerization of TGF-b
receptors and, subsequently, downstream SMAD signaling.
PAR1 scaffolding thus represents a regulatory mechanism
in ESC differentiation to the EC lineage.EXPERIMENTAL PROCEDURES
Reagents
J1 mESC cell line was purchased from American Type Cul-
ture Collection. The anti-VE-cadherin antibody (sc-9989),
anti-NANOG (sc-134218), anti-TGFbRI (sc-398, sc-33933), anti-
TGFbRII (sc-400, sc-17792), anti-PAR1 (sc-5605), anti-63His rabbit
antibody (sc-803), anti-63His mouse antibody (sc-8036), and anti-
a-actin (sc-32251) antibodies were from SantaCruz Biotechnology.
Anti-VE-cadherin antibody (AF1002), recombinant mouse TGF-b1
(7666-MB-005), and Mouse TER-119 antibody (MAB1125, targets
erythrocytes) were from R&D Systems. Alexa Fluor 633 goat anti-
rat immunoglobulin G (IgG) (H+L) (A21092, Life Technologies)
was used as secondary antibody for detecting TER-119. Collagen
IV-coated 6-well plate (354428) and Matrigel were from BD Biosci-
ences. Anti-CD31 antibody (550274) was purchased from BD
Biosciences/Pharmingen. Anti-FLK1 antibody (136404) was pur-
chased from Biolegend. Anti-SMAD2/3 (3102), anti-phospho-
SMAD2 (3108), and anti-FLK1 (2479) antibodies were from Cell
Signaling Technology. The PAR1 agonist peptide (TFLLRNPNDK-1056 Stem Cell Reports j Vol. 7 j 1050–1058 j December 13, 2016NH2) was synthesized and purified at the Research Resource Center
at the University of Illinois, Chicago.
GPCR Screening
mRNA was isolated from mESC and FACS-sorted FLK1+/VE-cad-
herin+mESC-ECs. cDNAwas generated and aGPCR screenwas per-
formed in S.O.’s laboratory. Real-time qPCR was performed using
the Universal ProbeLibrary, LightCycler 480 Probes Master, and
LightCycler 480 II (Roche Applied Sciences). Genomic DNA from
mouse tissue was used for quantification. All primer sequences
and probes used in the GPCR screen are listed in the supplemental
Excel files (forward primers in Table S1 and reverse primers in
Table S2). The Ct/Cp value of 15 ng cDNA was compared with
the Ct value of 3 ng genomic DNA to calculate the copy number
of genes in this cDNA library.
Cell Culture
mESCs were maintained on mitomycin C-treated mouse embry-
onic fibroblast (MEF) feeders in mESC growth medium. Before
differentiation, mESCs were cultured on MEF-free gelatin-coated
6-well dishes for 2 days in mESC growth medium (pre-condition-
ing). To start differentiation, we seeded pre-conditioned mESCs
in mouse collagen IV-coated 6-well dishes at a density of 3,000
cells/well in serum-free differentiation medium (75% IMDM,
25% Ham’s F12 medium) supplemented with N-2, B-27 (without
vitamin A), 0.05% BSA, 4.5 3 104 M 1-thioglycerol (MTG),
0.5 mM ascorbic acid, 10 ng/mL BMP-4, 50 ng/mLVEGF165, and
10 ng/mL basic fibroblast growth factor (bFGF) as described by us
for 7 days (Kohler et al., 2013).
Plasmid Constructs and Lentivirus Preparation
Human PAR1 cDNA plasmids with FLAG tag were purchased from
Addgene (Plasmid #53226) and subcloned into pLVX-IRES-puro
lentivirus vector (Clontech) or adenovirus vector Adeno-X3 (Clon-
tech). Human TGFbRII cDNA plasmid with HA tag (24801) and
human TGFbRI cDNA plasmid with 63His tag (19161) were pur-
chased from Addgene. The small double-strand hairpin shRNA
for PAR1 was designed by Block-iT RNAi Designer (Invitrogen),
synthesized by Integrated DNA Technologies (IDT), and inserted
into a pLL3.7 lentivirus vector (Addgene, 11795) or pLKO.1-puro
lentivirus vector (Addgene, 8453). PAR1 shRNA in a pLKO1 lentivi-
ral vector with puromycin selection was used to obtain a PAR1-KD
population. For in vivo studies, we used PAR1 shRNA or scramble
control shRNA in a pLL3.7 lentiviral vector expressing EGFP to
track the in vivo fate of the cells. The targeting sequence for
mouse PAR1 shRNA is 50-GGTAGGGCAGTCTACTTAA-30. The
guide RNA targeting sequence in mouse PAR1 gene for Cas9-medi-
ated CRISPR knockout used in this study is 50-GAACACAATCGTG
TACACGG-30. DNAoligoswere synthesized by IDTand cloned into
pLx-single guide RNA (sgRNA) lentivirus vector (Addgene, 50662)
(Wang et al., 2014). Lentivirus was prepared as reported by Gong
et al. (2015) and was used to transduce J1 mESCs in the presence
of 6 mg/mL polybrene. FLAG-PAR1 adenovirus was produced and
amplified in 293A cells. For the Cas9-mediated CRISPR knockout
experiment, sgRNA-expression J1 mESCs generated by 10 mg/mL
blasticidin selection were infected with Cas9-EGFP adenovirus
(Vector Biolabs) at an MOI of 50 twice, and EGFP-positive cells
were sorted by FACS and seeded in 96-well plates. The subpopula-
tion harboring PAR1 deletion by CRISPR/Cas9 was verified by
western blot and T7 endonuclease I (T7E1) assay.
Matrigel Plug Assay
The animal experiments were approved by the Animal Care Com-
mittee and the Institutional Animal Care and Use Committee
(IACUC) of the University of Illinois, Chicago. Experiments were
made according to IACUC and NIH guidelines. EGFP-transduced
mESC underwent lentiviral knockdown with scramble control
shRNA or PAR1-shRNA. A third group consisted of EGFP-trans-
duced mESC in which shRNA-mediated knockdown was rescued
by hPAR1 re-expression. These three ESC groups underwent differ-
entiation into ESC-ECs and were purified by CD31-conjugated
magnetic beads. ESC-ECs (5 3 105) were injected subcutaneously
into 3-month-old athymic nude mice (Harlan Laboratory) in a
suspension of 250 mL of Matrigel supplemented with 50 ng/mL
VEGF and 20 ng/mL bFGF. Matrigel plugs were retrieved 7 days
after transplantation, equilibrated in 30% sucrose overnight, and
embedded in OCT compound before freezing and cryosectioning.
For quantification of blood vessels in Matrigel, H&E staining was
performed.
Immunofluorescence and Confocal Microscopy
Frozen sections were fixed with 4% paraformaldehyde and per-
meabilized with 0.1% Triton X-100. Slides were probed with
primary antibodies and fluorescence-conjugated secondary anti-
bodies (Alexa Fluor 633, Life Technologies). Images were taken
with a Carl Zeiss confocal microscope.
Co-immunoprecipitation Assay
This assay was performed as reported by Gong et al. (2010, 2015).
Clarified cell lysates from PAR1-depleted mESCs and control cells
or 15 mM PAR1-AP or 10 ng/mL TGF-b1 stimulated cells were incu-
bated with anti-TGFbRII antibody, and subsequently with protein
A/G-conjugated Sepharose beads. Co-immunoprecipitated pro-
teins were analyzed by western blot as indicated in figures. In
some experiments involved in PAR1, TGFbRI, or TGFbRII overex-
pression, adenovirus encoding FLAG-PAR1 was used to transduce
mESCs, and plasmids encoding FLAG-PAR1, HA-TGFbRII, and
63His-TGFbRI were used to transfect 293T cells.
Flow Cytometry
This assay was performed on a BD LSRFortessa cell analyzer. For
labeling of cell surface proteins, 0.05% trypsin-EDTA detached
mESC-ECs were resuspended in 1 mL of differentiation medium
and incubated at 37C for 1 hr. Antibodies diluted in washing
buffer (0.2% BSA in PBS) were added afterward and incubated
for 1 hr at room temperature. After two washes, the cells were
resuspended in washing buffer and analyzed immediately by
flow cytometry. Mouse IgG1 kappa and rat IgG2a kappa were
used as negative controls for FACS gating.
Statistics
Western blot bands were scanned and analyzed for uncalibrated
optical density using NIH ImageJ software. ANOVA and Student’st test (two-tailed) were used to determine statistical significance
with a p-value threshold set at <0.05.
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